Rhabdoid Carcinoma of the Rectum.
- Author:
Narimantas Evaldas SAMALAVICIUS
1
;
Rokas STULPINAS
;
Valdas GASILIONIS
;
Edita BALTRUSKEVICIENE
;
Eduardas ALEKNAVICIUS
;
Ugnius MICKYS
Author Information
- Publication Type:Case Report
- Keywords: Rhabdoid tumor; Carcinoma; Rectum; BRAF; INI1
- MeSH: Colon; Drug Therapy; Fluorouracil; Humans; Male; Microsatellite Instability; Middle Aged; Rectum*; Rhabdoid Tumor; Vimentin
- From:Annals of Coloproctology 2013;29(6):252-255
- CountryRepublic of Korea
- Language:English
- Abstract: Rhabdoid colonic tumors are very rare lesions with just a few publications describing such neoplasms. Even more unusual for these lesions are their primary rectal locations, with only two brief case reports having been published on that subject to date. We present a case of a composite rhabdoid rectal carcinoma in a 49-year-old male. The tumor behaved very aggressively, with rapid patient demise despite radical surgery and intensive postoperative chemotherapy (FOLFIRI [folinic acid {leucovorin}, fluorouracil {5-fluorouracil}, and irinotecan] and FOLFOX4 [folinic acid {leucovorin}, fluorouraci {5-fluorouracil}, and oxaliplatin]). Pathologic examination was supportive of a rhabdoid carcinoma, with a compatible immunohistochemical profile, demonstrating synchronous expression of vimentin and epithelial markers in the tumor cells. In addition, BRAF V600E gene mutation, together with a wild-type KRAS gene, was identified, and no evidence of microsatellite instability based on MLH1, MSH2, MSH6, and PMS2 immunophenotypes, i.e., no loss of expression for all 4 markers, was observed. Our reported case confirms previously published observations of the clinical aggressiveness and the poor therapeutic response for rhabdoid tumors.
